Innospec [IOSP] vs Ingevity [NGVT] Detailed Stock Comparison
Innospec
NASDAQ
Loading...
Ingevity
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Innospec wins in 9 metrics, Ingevity wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Innospec | Ingevity | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 102.32 | 12.96 | Ingevity |
| Price-to-Book Ratio | 1.53 | 14.48 | Innospec |
| Debt-to-Equity Ratio | 3.79 | 1,102.15 | Innospec |
| PEG Ratio | 12.75 | 11.82 | Ingevity |
| EV/EBITDA | 28.64 | 6.92 | Ingevity |
| Profit Margin (TTM) | 1.08% | -16.35% | Innospec |
| Operating Margin (TTM) | 7.96% | 23.53% | Ingevity |
| EBITDA Margin (TTM) | 7.96% | 23.53% | Ingevity |
| Return on Equity | 1.55% | -106.83% | Innospec |
| Return on Assets (TTM) | 0.65% | 8.86% | Ingevity |
| Free Cash Flow (TTM) | $122.20M | $51.00M | Innospec |
| Dividend Yield | 1.97% | N/A | N/A |
| 1-Year Return | -23.47% | 43.98% | Ingevity |
| Price-to-Sales Ratio (TTM) | 1.11 | 1.32 | Innospec |
| Enterprise Value | $1.77B | $2.74B | Ingevity |
| EV/Revenue Ratio | 0.99 | 2.07 | Innospec |
| Gross Profit Margin (TTM) | 28.02% | 39.93% | Ingevity |
| Revenue per Share (TTM) | $72 | $36 | Innospec |
| Earnings per Share (Diluted) | $0.78 | $-9.75 | Innospec |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Innospec vs Ingevity Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Innospec | 2.04% | 3.68% | -8.27% | -12.81% | -26.62% | -24.34% |
| Ingevity | 1.50% | 26.91% | 9.57% | 27.25% | 15.58% | 29.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Innospec | -23.47% | -18.11% | 3.64% | 75.82% | 598.46% | 905.43% |
| Ingevity | 43.98% | -31.74% | -15.58% | 93.47% | 93.47% | 93.47% |
Performance & Financial Health Analysis: Innospec vs Ingevity
| Metric | IOSP | NGVT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.99B | $1.75B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 234,810 | 225,243 |
| 90 Day Avg. Volume | 227,103 | 215,541 |
| Last Close | $81.44 | $51.27 |
| 52 Week Range | $74.10 - $128.35 | $28.49 - $52.05 |
| % from 52W High | -36.55% | -1.50% |
| All-Time High | $133.71 (May 06, 2024) | $120.41 (Feb 18, 2019) |
| % from All-Time High | -39.09% | -57.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | -0.07% |
| Quarterly Earnings Growth | -0.25% | -0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | -0.16% |
| Operating Margin (TTM) | 0.08% | 0.24% |
| Return on Equity (TTM) | 0.02% | -1.07% |
| Debt to Equity (MRQ) | 3.79 | 1,102.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $52.19 | $3.31 |
| Cash per Share (MRQ) | $10.69 | $2.11 |
| Operating Cash Flow (TTM) | $136.80M | $215.40M |
| Levered Free Cash Flow (TTM) | $-56,962,500 | $357.79M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.97% | N/A |
| Last 12-Month Dividend | $1.63 | N/A |
Valuation & Enterprise Metrics Analysis: Innospec vs Ingevity
| Metric | IOSP | NGVT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 102.32 | 12.96 |
| Forward P/E | 12.75 | 11.82 |
| PEG Ratio | 12.75 | 11.82 |
| Price to Sales (TTM) | 1.11 | 1.32 |
| Price to Book (MRQ) | 1.53 | 14.48 |
| Market Capitalization | ||
| Market Capitalization | $1.99B | $1.75B |
| Enterprise Value | $1.77B | $2.74B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.99 | 2.07 |
| Enterprise to EBITDA | 28.64 | 6.92 |
| Risk & Other Metrics | ||
| Beta | N/A | N/A |
| Book Value per Share (MRQ) | $52.19 | $3.31 |
Financial Statements Comparison: Innospec vs Ingevity
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IOSP | NGVT |
|---|---|---|
| Revenue/Sales | $440.80M | $284.00M |
| Cost of Goods Sold | $315.70M | $170.60M |
| Gross Profit | $125.10M | $113.40M |
| Research & Development | $12.70M | $7.70M |
| Operating Income (EBIT) | $43.00M | $62.60M |
| EBITDA | $54.10M | $83.20M |
| Pre-Tax Income | $44.40M | $26.80M |
| Income Tax | $11.60M | $6.30M |
| Net Income (Profit) | $32.80M | $20.50M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IOSP | NGVT |
|---|---|---|
| Cash & Equivalents | $299.80M | $71.50M |
| Total Current Assets | $977.10M | $530.00M |
| Total Current Liabilities | $357.60M | $264.60M |
| Long-Term Debt | $30.40M | $1.37B |
| Total Shareholders Equity | $1.27B | $234.60M |
| Retained Earnings | $1.06B | $592.50M |
| Property, Plant & Equipment | $321.50M | $45.90M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IOSP | NGVT |
|---|---|---|
| Operating Cash Flow | $21.70M | $32.70M |
| Capital Expenditures | $100,000 | N/A |
| Free Cash Flow | $12.70M | $15.40M |
| Debt Repayment | N/A | $-100.30M |
| Common Stock Repurchase | $-4.80M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IOSP | NGVT |
|---|---|---|
| Shares Short | 260,930 | 1.21M |
| Short Ratio | 1.09 | 5.78 |
| Short % of Float | 0.01% | 0.05% |
| Average Daily Volume (10 Day) | 234,810 | 225,243 |
| Average Daily Volume (90 Day) | 227,103 | 215,541 |
| Shares Outstanding | 24.96M | 36.35M |
| Float Shares | 24.63M | 36.22M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.00% | 1.03% |
Dividend Analysis & Yield Comparison: Innospec vs Ingevity
| Metric | IOSP | NGVT |
|---|---|---|
| Last 12-Month Dividend | $1.63 | N/A |
| Last 12-Month Dividend Yield | 1.97% | N/A |
| 3-Year Avg Annual Dividend | $1.48 | N/A |
| 3-Year Avg Dividend Yield | 0.70% | N/A |
| 3-Year Total Dividends | $4.45 | N/A |
| Ex-Dividend Date | May 20, 2025 | N/A |